Information Provided By: 
Fly News Breaks for September 13, 2017
ICPT
Sep 13, 2017 | 08:40 EDT
JMP Securities analyst Liisa Bayko said the warning letter sent by Intercept to health care providers regarding post-marketing reports of liver issues and death in certain PBC patients highlights risks that were already known and doesn't change her fundamental view on Ocaliva. The analyst, who sees little read through to the ongoing Phase 3 REGENERATE trial in NASH patients and views yesterday's drop in Intercept shares as an overreaction, keeps an Outperform rating and $150 price target on the stock.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
